Blood–Brain Barrier in Drug Discovery – Optimizing Brain Exposure of CNS Drugs and Minimizing Brain Side Effects for Peripheral Drugs
Autor L Dien Limba Engleză Hardback – 26 ian 2015
Preț: 978.15 lei
Preț vechi: 1029.63 lei
-5% Nou
Puncte Express: 1467
Preț estimativ în valută:
187.21€ • 194.69$ • 156.66£
187.21€ • 194.69$ • 156.66£
Carte tipărită la comandă
Livrare economică 14-28 martie
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9781118788356
ISBN-10: 1118788354
Pagini: 608
Dimensiuni: 164 x 243 x 38 mm
Greutate: 0.92 kg
Editura: Wiley
Locul publicării:Hoboken, United States
ISBN-10: 1118788354
Pagini: 608
Dimensiuni: 164 x 243 x 38 mm
Greutate: 0.92 kg
Editura: Wiley
Locul publicării:Hoboken, United States
Public țintă
Central nervous system (CNS) drug discovery scientists, brain researchers, neuroscientists, drug metabolism and pharmacokinetic scientists, medicinal chemists, modelling and simulation scientists, biologists, pharmacologists, biochemists, biophysicists, toxicologists, pharmaceutical scientists, analytical chemists, graduate students, and postdoctoral fellowsBrain, neuroscience, pharmaceutical research, CNS drug discovery, brain drug disposition, pharmacokinetics
Notă biografică
Li Di is an associate research fellow in the Pharmacokinetics, Dynamics, and Drug Metabolism Department at Pfizer Global Research and Development and has extensive experience in the pharmaceutical industry. She has over 100 publications, presented over 70 invited lectures, and teaches an American Chemical Society short course on drug-like properties. Edward Kerns worked in pharmaceutical research and development for over 30 years, was associate director at Wyeth and Bristol-Myers Squibb, then was at the NIH-National Center for Advancing Translational Sciences. He published over 90 journal papers or book chapters and 3 books, and teaches an American Chemical Society short course on drug-like properties.